Citation Impact
Citing Papers
p53: puzzle and paradigm.
1996 Standout
Expression of the HPV16 E7 gene generates proliferation in stratified squamous cell cultures which is independent of endogenous p53 levels.
1992
Regulation of p53 stability by Mdm2
1997 StandoutNature
WAF1, a potential mediator of p53 tumor suppression
1993 Standout
The human papillomavirus E7 protein as a transforming and transactivating factor
1993
Human papillomavirus oncoproteins: pathways to transformation
2010 Standout
Papillomavirus infections — a major cause of human cancers
1996 StandoutNobel
Classification of papillomaviruses
2004 StandoutNobel
Loss of Net as Repressor Leads to Constitutive Increased c-fos Transcription in Cervical Cancer Cells
2004 StandoutNobel
The Human Papillomavirus E6 protein and its contribution to malignant progression
2001
Head and neck cancer
2008 Standout
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
1993 Standout
The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway
2004
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
1991
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
The Human Papillomavirus 16 E6 Protein Binds to Fas-associated Death Domain and Protects Cells from Fas-triggered Apoptosis
2004
The influence of the boost in breast-conserving therapy on cosmetic outcome in the eortc “boost versus no boost” trial
1999
The predominant mRNA class in HPV16‐infected genital neoplasias does not encode the e6 or the E7 protein
1993
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
The role of the E6-p53 interaction in the molecular pathogenesis of HPV
1999
Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity
1998
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
1999 Standout
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue
2000 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers
2000 Standout
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
1992 Standout
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
2006 Standout
Papillomaviruses and cancer: from basic studies to clinical application
2002 StandoutNobel
Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system
1994 StandoutNobel
Human papillomavirus and cervical cancer
2007 Standout
Human papillomavirus immortalization and transformation functions
2002
The papillomavirus E6 proteins
1998
Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix
1994 StandoutNobel
Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts
1994
Serologic Response to Human Papillomavirus Type 16 (HPV-16) Virus-like Particles in HPV-16 DNA-Positive Invasive Cervical Cancer and Cervical Intraepithelial Neoplasia Grade III Patients and Controls from Colombia and Spain
1995
The Human Papillomavirus E7 Oncoprotein Functionally Interacts with the S4 Subunit of the 26 S Proteasome
1997
Oncogenic DNA viruses
2001 StandoutNobel
Inhibitors of mammalian G1 cyclin-dependent kinases.
1995 Standout
The Emerging p53 Gene Family
1999 StandoutNobel
The Tumor Suppressor Protein p16 and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring Lysine-less Proteins That Are Degraded by the Ubiquitin System
2004 StandoutNobel
The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
1994 Standout
Selective down-regulation of human papillomavirus transcription by 2-deoxyglucose
1998 StandoutNobel
Genetic complementation to non-tumorigenicity in cervical-carcinoma cells correlates with alterations in AP-1 composition
2000 StandoutNobel
Transactivation of Prothymosin α and c-mycPromoters by Human Papillomavirus Type 16 E6 Protein
1997
Cellular transformation by papilomavirus oncorproteins
1993
Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex
1999 StandoutNobel
Inhibition of Papillomavirus Protein Function in Cervical Cancer Cells by Intrabody Targeting
2005 StandoutNobel
The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
1992
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes
1992
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription.
1992
Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development.
1994
Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
2001 StandoutNobel
The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis
1999 Standout
Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation
1996
Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas.
1994
Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region
1993
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Inhibition of p53 DNA binding by human papillomavirus E6 proteins
1994
Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes.
1995
Activation of the c-fos gene by the HPV16 oncoproteins depends upon the cAMP-response element at -60
1994
Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes
1992
The p53-mdm-2 autoregulatory feedback loop.
1993 Standout
Antiviral Actions of Interferons
2001 Standout
The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein
1993
Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16
1992
Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins.
1992
Mechanisms Underlying Ubiquitination
2001 Standout
Disturbance of Tumor Necrosis Factor Alpha-Mediated Beta Interferon Signaling in Cervical Carcinoma Cells
2002 StandoutNobel
Increased Incidence of Squamous Cell Carcinomas in Mastomys natalensis Papillomavirus E6 Transgenic Mice during Two-Stage Skin Carcinogenesis
2004 StandoutNobel
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.
1995 StandoutNobel
Telomerase activation: one step on the road to cancer?
1999 StandoutNobel
Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription
1997 StandoutNobel
Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73
1998 StandoutNobel
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
1994 StandoutNobel
Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2
1994 StandoutNobel
A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies
2003 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
2001 StandoutNobel
Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene.
1998
Human Papillomavirus Type 16 E6 Induces Self-Ubiquitination of the E6AP Ubiquitin-Protein Ligase
2000
Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses
2005 StandoutNobel
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53
1993
Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1
1994
Works of J.A. Haas being referenced
The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy
1996
The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture
1991